Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

QTRX - Quanterix Corporation So'nggi Yangiliklar | Finranks

Home

/

QTRX

Q

Quanterix Corporation (QTRX)

NGM – Real vaqt narxi. Valyuta: USD

2.66

+0.04 (1.52%)

Bozor ochiq: Aug 12, 2026, 11:57 AM EDT

2.59

-0.04 (-1.33%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Quanterix Q2 Earnings Call Highlights

Quanterix Q2 Earnings Call Highlights

Quanterix NASDAQ: QTRX reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May.

Quanterix Names Jim Gute Chief Commercial Officer

Quanterix Names Jim Gute Chief Commercial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company's commercial operations. “We are thrilled to attract commercial leadership of Jim's caliber to Quanterix, at a pivotal time, ahead of our expansion in diagnostics and with renewed focu.

Quanterix Releases Financial Results for the Second Quarter of 2026

Quanterix Releases Financial Results for the Second Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to im.

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat that will be webcast live on 1:00 pm ET on Wednesday, August 12th, during which he will provide an update on the C.

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results. Quanterix will issue a press release regarding its second quarter 2026 financial results prior to the conference call on Monday, August 10, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.c.

Videolar

No Data

There is no data to display

Press-relizlar

Quanterix Names Jim Gute Chief Commercial Officer

Quanterix Names Jim Gute Chief Commercial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company's commercial operations. “We are thrilled to attract commercial leadership of Jim's caliber to Quanterix, at a pivotal time, ahead of our expansion in diagnostics and with renewed focu.

Quanterix Releases Financial Results for the Second Quarter of 2026

Quanterix Releases Financial Results for the Second Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to im.

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat that will be webcast live on 1:00 pm ET on Wednesday, August 12th, during which he will provide an update on the C.